Free Trial
NASDAQ:ANIX

Anixa Biosciences 1/10/2025 Earnings Report

Anixa Biosciences logo
$2.72 -0.03 (-1.09%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.98 +0.26 (+9.52%)
As of 04/17/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Anixa Biosciences' Q2 2025 earnings is scheduled for Tuesday, June 3, 2025

Conference Call Resources

Anixa Biosciences Earnings Headlines

Anixa Biosciences receives notice of allowance for new patent from USPTO
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

View Anixa Biosciences Profile

More Earnings Resources from MarketBeat